Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Target Rybelsus Among New FDA Product-Specific Guidances

Agency’s Running Total Of PSGs Approaches 2,000 Landmark

Executive Summary

The latest tranche of product-specific guidances for generic development has been published by the US FDA, following two released in March and May this year.

You may also be interested in...



Sandoz Eyes In-House GLP-1 Development – Apart From ‘Key’ APIs

With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.

FDA Directs On Glenmark’s Ryaltris With New Batch Of Guidances

A batch of four dozen new and revised product-specific guidances for generic products has been published by the US Food and Drug Administration, spanning a range of routes, dosages, and therapeutic areas.

Apotex Launches Apparent First Abraxane Generic – With Little Fanfare

Apotex has confirmed launch of a generic version of Bristol Myers Squibb’s Abraxane, with details thin on the ground.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel